🔗 Share this article

As America undertakes sweeping revisions to its vaccination schedules, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by questioning coronavirus vaccines in the global health crisis and has zeroed in on potential deaths after Covid immunization in her recent time at the FDA.

Proposed Changes to Pediatric Immunization Schedule

Public health authorities had intended to unveil radical revisions to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of step with much of the international standard with insufficient data for benefit. The planned update has been delayed until the new year.

Rather than the top vaccines chief, Dr. Høeg is listed to present at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for discontinuing certain pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a society with universal health coverage and a population about the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – typically the purview of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has little discernible track record in pharmaceutical research, regulation or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Previous heads of the center would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she lacks the type of experience that former directors who ran CBER have had.”

CDER has an enormous portfolio at the FDA, Woodcock emphasized.

“Many people just focuses on the innovative therapies, but the generic drug division authorizes thousands of generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and every single one have to be looked after,” Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the role, which manages in excess of 5,000 staff members. “It’s a huge administrative position, if you do it right,” the former official concluded.

Agency Reaction and Contentious Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among FDA leaders on vaccines, a spokesperson said that the “concerns rely on incorrect assumptions”.

“Her resume matches the functions of her position,” the official said, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a disputed rapid medication authorization process that reportedly concerned her preceding directors. “By what process are these medications being picked for this voucher program? Who is making the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he said, “the FDA looks to be trending towards more relaxed regulations of pharmaceuticals, aside from immunizations.”

Established History on Vaccines

With immunizations, Høeg has a more established, if problematic, track record, some experts observe. She published a analysis using unverified crowd-sourced reports to determine the rate of myocarditis following COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the new administration featured altering guidelines for novel immunizations and ending “unnecessary” vaccines, she said post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of excluding young men from obtaining Covid vaccinations.

“She is an complete ideologue who commences with her conclusions and works backwards to accommodate the evidence in a extremely misleading, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other dissenters, {like|